Compare RCUS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | ARQT |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 2018 | 2020 |
| Metric | RCUS | ARQT |
|---|---|---|
| Price | $23.88 | $29.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | ★ $29.38 | $24.83 |
| AVG Volume (30 Days) | ★ 2.0M | 1.8M |
| Earning Date | 10-28-2025 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $240,000,000.00 | ★ $317,929,000.00 |
| Revenue This Year | N/A | $85.51 |
| Revenue Next Year | N/A | $30.74 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 129.21 |
| 52 Week Low | $6.50 | $11.13 |
| 52 Week High | $26.40 | $31.77 |
| Indicator | RCUS | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 56.35 |
| Support Level | $22.60 | $27.71 |
| Resistance Level | $23.62 | $30.26 |
| Average True Range (ATR) | 1.13 | 1.02 |
| MACD | -0.12 | -0.24 |
| Stochastic Oscillator | 62.61 | 74.59 |
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.